Relmada Therapeutics, Inc.: Form 10-K for the period ended Jun 30, 2016
Filed with the SEC on Sep 9, 2016 and accepted by EDGAR at Sep 9, 2016, 17:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2015-07-01 to 2016-06-30 | $6.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2015-07-01 to 2016-06-30 | −$16.2m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2015-07-01 to 2016-06-30 | −$3.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2015-07-01 to 2016-06-30 | −$0.26 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2015-07-01 to 2016-06-30 | −$13.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2015-07-01 to 2016-06-30 | $562.3k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2016-06-30 | $8.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $9.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $10.2m | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $3.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-06-30 | $3.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-06-30 | $7.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-16-016664. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.